The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Research > Ribapharm Inc.

Ribapharm Inc.
 PROFILE
Ribapharm is what you get when you rip apart ICN Pharmaceuticals. One of three entities resulting from the split of the embattled drugmaker, biotech firm Ribapharm will research and develop anti-viral and cancer drugs with its library of more than 3,500 nucleoside analog compounds (small-molecule-type chemicals similar to human and viral DNA and RNA). Ribapharm will continue to out-license antiviral drug Ribavirin, which Schering-Plough markets as a part of its hepatitis C therapy. Other products in development include Tiazole (leukemia treatment) and Adenazole (colon cancer treatment). After Ribapharm's planned IPO, ICN will control more than 95% of the company's voting power.

 COMPETITION
Amgen Inc. (AMGN)
Chiron Corporation (CHIR)
Chugai Pharmaceutical Co., Ltd. (dossier)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
2000 Sales (mil.): 154.80
1-Yr. Sales Growth: 41.3%
Employees: 113
Revenue per employee: $1,369,911.50

 KEY PEOPLE

• Bill A. MacDonald
    CFO

 CONTACT INFO
3300 Hyland Ave.
Costa Mesa, CA 92626
US
Phone: 714-545-0100
Fax: -

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001